Axa S.A. Rocket Pharmaceuticals, Inc. Transaction History

Axa S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$43.34 - $65.91 $7.41 Million - $11.3 Million	-170,863 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$23.3 - $59.57 $962,825 - $2.46 Million	-41,323 Reduced 19.47%	170,863 $9.37 Million
Q3 2020 Nov 13, 2020	SELL	$20.5 - $28.59 $45,879 - $63,984	-2,238 Reduced 1.04%	212,186 $4.85 Million
Q2 2020 Aug 14, 2020	BUY	$13.32 - $22.61 $146,426 - $248,551	10,993 Added 5.4%	214,424 $4.49 Million
Q1 2020 May 15, 2020	SELL	$9.71 - $25.11 $147,475 - $381,370	-15,188 Reduced 6.95%	203,431 $2.84 Million
Q4 2019 Feb 18, 2020	BUY	$11.07 - $24.23 $51,320 - $112,330	4,636 Added 2.17%	218,619 $4.98 Million
Q3 2019 Nov 14, 2019	SELL	$10.85 - $14.78 $4,112 - $5,601	-379 Reduced 0.18%	213,983 $2.49 Million
Q2 2019 Aug 13, 2019	BUY	$15.0 - $19.81 $70,170 - $92,671	4,678 Added 2.23%	214,362 $3.22 Million
Q1 2019 May 14, 2019	BUY	$13.45 - $19.01 $643,663 - $909,742	47,856 Added 29.57%	209,684 $3.68 Million
Q4 2018 Feb 13, 2019	BUY	$11.21 - $23.53 $372,239 - $781,337	33,206 Added 25.82%	161,828 $2.4 Million
Q3 2018 Nov 08, 2018	BUY	$18.5 - $25.49 $2.38 Million - $3.28 Million	128,622 New	128,622 $3.17 Million

209

93.2M

319K

70.3K

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $1.07B
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.